Paperbase

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus

Vausselin, T. Seron, K. Lavie, M. Mesalam, A. A. Lemasson, M. Belouzard, S. Feneant, L. Danneels, A. Rouille, Y. Cocquerel, L. Foquet, L. Rosenberg, A. R. Wychowski, C. Meuleman, P. Melnyk, P. Dubuisson, J.

Journal of virology, 2016-10

https://doi.org/10.1128/jvi.00404-16

Sandrine Belouzard

Belouzard Sandrine

ORCID: 0000-0002-9972-4054

Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus 10.1128/JVI.00404-16

Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication 10.1111/cmi.12572

Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin 10.1016/j.antiviral.2016.07.011

Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans 10.1128/JVI.03647-14

Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro 10.1371/journal.pone.0142539

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A 10.1128/JVI.00192-15

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/JVI.01473-15

Regulation of core expression during the hepatitis C virus life cycle 10.1099/vir.0.070433-0

Successful Anti-Scavenger Receptor Class B Type I (SR-BI) Monoclonal Antibody Therapy in Humanized Mice After Challenge With HCV Variants With In Vitro Resistance to SR-BI-Targeting Agents 10.1002/hep.27196

Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells 10.1371/journal.pone.0074491

Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus 10.1371/journal.pone.0070809

The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus 10.1002/hep.26273

Utilization of human DC-SIGN and L-SIGN for entry and infection of host cells by the New World arenavirus, Junin virus 10.1016/j.bbrc.2013.10.106

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry 10.1002/hep.24803

Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein 10.3390/v4061011

Role of low-density lipoprotein receptor in the hepatitis C virus life cycle 10.1002/hep.25501

Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway 10.1074/jbc.M111.224857

Griffithsin Has Antiviral Activity against Hepatitis C Virus 10.1128/AAC.00633-11

Hepatitis C virus entry into the hepatocyte 10.2478/s11535-011-0076-y

Elastase-mediated Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein at Discrete Sites within the S2 Domain 10.1074/jbc.M110.103275

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites 10.1073/pnas.0809524106

Characterization of a Highly Conserved Domain within the Severe Acute Respiratory Syndrome Coronavirus Spike Protein S2 Domain with Characteristics of a Viral Fusion Peptide 10.1128/JVI.00079-09

SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion 10.1016/j.virol.2009.07.038

Molecular architecture of the bipartite fusion loops of vesicular stomatitis virus glycoprotein G, a class III viral fusion protein 10.1074/jbc.M708955200

Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity 10.1073/pnas.0706671104

Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway. 10.1074/jbc.m400508200

Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. 10.1074/jbc.m406315200

Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis. 10.1128/jvi.79.16.10826-10829.2005

Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis. 10.1038/sj.emboj.7600989

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. 10.1128/jvi.80.6.2832-2841.2006

Entry and release of hepatitis C virus in polarized human hepatocytes. 10.1128/JVI.00478-17

Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll-Like Receptor 3 in Hepatocytes 10.1053/j.gastro.2018.03.020

The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal 10.1074/jbc.RA119.008964

Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers 10.1101/2020.05.12.20098236

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress. 10.3390/cells10082047

Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication. 10.1128/aac.00097-21

Muriel Lavie

Lavie Muriel

ORCID: 0000-0003-3308-811X

Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly. 10.1016/j.biochi.2017.06.009

Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. 10.1128/jvi.00048-17

Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle. 10.1089/hum.2016.108

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. 10.1128/jvi.00404-16

Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. 10.1128/jvi.01402-14

Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis. 10.1016/j.virol.2013.09.019

Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. 10.1007/s00262-012-1279-4

The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry. 10.1186/1471-2180-9-111

Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. 10.1111/j.1462-5822.2007.01070.x

Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. 10.1002/hep.21406

Distribution and sequence analysis of a family of type ill-dependent effectors correlate with the phylogeny of Ralstonia solanacearum strains. 10.1094/mpmi.2004.17.8.931

PopP1, a new member of the YopJ/AvrRxv family of type III effector proteins, acts as a host-specificity factor and modulates aggressiveness of Ralstonia solanacearum. 10.1094/mpmi.2002.15.10.1058

Genome sequence of the plant pathogen Ralstonia solanacearum. 10.1038/415497a

Laurence Cocquerel

Cocquerel Laurence

ORCID: 0000-0002-2136-5178

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus 10.1128/jvi.00404-16

Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro 10.1371/journal.pone.0142539

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A 10.1128/jvi.00192-15

SRFBP1, an Additional Player in HCV Entry 10.1016/j.tim.2015.08.003

CD81 and Hepatitis C Virus (HCV) Infection 10.3390/v6020535

Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein 10.1371/journal.pone.0111333

EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry 10.1111/cmi.12112

The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus 10.1002/hep.26273

Structural Basis of Ligand Interactions of the Large Extracellular Domain of Tetraspanin CD81 10.1128/jv1.00559-12

Hepatitis C virus entry into the hepatocyte 10.2478/s11535-011-0076-y

Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, and Their Effect on Hepatitis C Virus Infection 10.1074/jbc.M111.220103

The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry 10.1186/1471-2180-9-111

The Ig Domain Protein CD9P-1 Down-regulates CD81 Ability to Support Plasmodium yoelii Infection 10.1074/jbc.M109.057927

Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry 10.1111/j.1462-5822.2007.01070.x

Early steps of the hepatitis C virus life cycle 10.1111/j.1462-5822.2007.01107.x

Entry of HCV into target cells 10.1684/vir.2008.0163

The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry 10.1371/journal.pone.0001866

Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins 10.1099/vir.0.82872-0

Hepatitis C virus entry: potential receptors and their biological functions 10.1099/vir.0.81646-0

Kinetics of HCV envelope proteins' interaction with CD81 large extracellular loop 10.1016/j.bbrc.2005.01.056

Characterization of functional hepatitis C virus envelope glycoproteins 10.1128/jvi.78.6.2994-3002.2004

Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions 10.1074/jbc.M406315200

CD81-dependent binding of hepatitis C virus E1E2 heterodimers 10.1128/jvi.77.19.10677-10683.2003

Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody 10.1128/jvi.77.2.1604-1609.2003

Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line 10.1093/glycob/12.2.95

Subcellular localization and topology of the p7 polypeptide of hepatitis C virus 10.1128/jvi.76.8.3720-3730.2002

Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins 10.1093/emboj/cdf295

Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins 10.1128/jvi.74.8.3623-3633.2000

Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein 10.1074/jbc.M004326200

Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval 10.1074/jbc.273.48.32088

[Occludin, an additional key for hepatitis C virus entry]. 10.1051/medsci/2009256-7549

HCV research 20 years after discovery: a summary of the 16th international symposium on hepatitis C virus and related viruses. 10.1053/j.gastro.2009.11.018

Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies. 10.1016/j.yexcr.2011.08.018

Structural basis of ligand interactions of the large extracellular domain of tetraspanin CD81. 10.1128/jvi.00559-12

Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. 10.1136/gutjnl-2015-311109

Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. 10.1053/j.gastro.2017.09.020

The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization. 10.1074/jbc.m003003200

Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication. 10.1111/cmi.12804

The Role of CD81 in HCV and Plasmodium Infection 10.1007/978-94-007-6070-7_14

Biogenesis of hepatitis C virus envelope glycoproteins 10.1099/0022-1317-82-11-2589

Endoplasmic reticulum retention of hepatitis C virus glycoprotein complex E1E2: A role for the transmembrane domain of E2 10.1016/s0248-4900(98)80287-6

Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2 10.1099/0022-1317-82-7-1629

SOLUTION STRUCTURE OF FRAGMENT (350-370) OF THE TRANSMEMBRANE DOMAIN OF HEPATITIS C ENVELOPE GLYCOPROTEIN E1 10.2210/pdb1emz/pdb

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17

New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle 10.1038/s41598-019-42737-2

Le virus de l’hépatite E, un virus méconnu qui se dévoile 10.1051/medsci/2018299

Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses 10.1099/jgv.0.001099

Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis 10.1093/infdis/jiz171

The fate of Hepatitis E virus capsid protein is regulated by an Arginine-Rich Motif 10.1101/2021.05.26.445820

In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus. 10.1007/s40203-021-00093-y

New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle 10.1101/435933

Yves Rouillé

Rouillé Yves

ORCID: 0000-0003-0788-9271

Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication 10.1111/cmi.12572

Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon 10.1016/s0014-5793(97)00892-2

Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1 10.1074/jbc.272.52.32810

Internal cleavage of the inhibitory 7B2 carboxyl-terminal peptide by PC2: A potential mechanism for its inactivation 10.1073/pnas.93.10.4919

DISTINCT HYDRO-OSMOTIC RECEPTORS FOR THE NEUROHYPOPHYSEAL PEPTIDES VASOTOCIN AND HYDRINS IN THE FROG RANA-ESCULENTA 10.1016/0143-4179(95)90039-x

HYPERPROINSULINAEMIA IN OBESE FAT/FAT MICE ASSOCIATED WITH A CARBOXYPEPTIDASE-E MUTATION WHICH REDUCES ENZYME-ACTIVITY 10.1038/ng0695-135

PROTEOLYTIC PROCESSING MECHANISMS IN THE BIOSYNTHESIS OF NEUROENDOCRINE PEPTIDES - THE SUBTILISIN-LIKE PROPROTEIN CONVERTASES 10.1006/frne.1995.1012

ACTION OF NEUROHYPOPHYSEAL GRANULE LYS-ARG ENDOPEPTIDASE ON SYNTHETIC POLYPEPTIDES COMPRISING THE PROCESSING SEQUENCE OF PROVASOPRESSIN-NEUROPHYSIN 10.1007/bf01200246

PROGLUCAGON IS PROCESSED TO GLUCAGON BY PROHORMONE CONVERTASE PC2 IN ALPHA-TC1-6 CELLS 10.1073/pnas.91.8.3242

SPECIAL EVOLUTION OF NEUROHYPOPHYSEAL HORMONES IN CARTILAGINOUS FISHES - ASVATOCIN AND PHASVATOCIN, 2 OXYTOCIN-LIKE PEPTIDES ISOLATED FROM THE SPOTTED DOGFISH (SCYLIORHINUS-CANICULUS) 10.1073/pnas.91.23.11266

A NEUROSECRETORY GRANULE LYS-ARG CA2+-DEPENDENT ENDOPEPTIDASE PUTATIVELY INVOLVED IN PROOXYTOCIN AND PROVASOPRESSIN PROCESSING 10.1016/0143-4179(92)90050-7

EVIDENCE FOR DISTINCT DIBASIC PROCESSING ENDOPEPTIDASES WITH LYS-ARG AND ARG-ARG SPECIFICITIES IN NEUROHYPOPHYSEAL SECRETORY GRANULES 10.1016/0006-291x(92)91618-z

PROCESSING ENDOPEPTIDASE DEFICIENCY IN NEUROHYPOPHYSEAL SECRETORY GRANULES OF THE DIABETES-INSIPIDUS (BRATTLEBORO) RAT 10.1007/bf01122032

HETEROLOGUE CONVERSION OF AMPHIBIAN HYDRIN-2 INTO VASOTOCIN THROUGH BOVINE GRANULE ALPHA-AMIDATING ENZYME 10.1111/j.1365-2826.1991.tb00233.x

NEUROHYPOPHYSEAL HORMONES AS MOLECULAR EVOLUTIONARY TRACERS - INVESTIGATIONS ON THE STURGEONS ACIPENSER-STELLATUS AND ACIPENSER-GULDENSTADTI 10.1016/0305-0491(91)90280-q

EVOLUTIONARY SPECIFICITY OF HYDRINS, NEW HYDROOSMOTIC NEUROPEPTIDES - OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY) IN THE TOAD BUFO-MARINUS BUT NOT IN THE VIPER VIPERA-ASPIS 10.1016/0014-5793(90)80783-f

IDENTIFICATION OF 2 TYPES OF NEUROPHYSINS IN XENOPUS-LAEVIS NEUROINTERMEDIATE PITUITARY HOMOLOGOUS TO MAMMALIAN MSEL-NEUROPHYSIN AND VLDV-NEUROPHYSIN 10.1016/0143-4179(90)90142-l

OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY), A NEW HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDE, IN SECRETORY GRANULES ISOLATED FROM THE FROG (RANA-ESCULENTA) NEUROINTERMEDIATE PITUITARY 10.1159/000125343

HYDRINS, HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDES - OSMOREGULATORY ADAPTATION IN AMPHIBIANS THROUGH VASOTOCIN PRECURSOR PROCESSING 10.1073/pnas.86.14.5272

ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOTOCIN, MESOTOCIN, MSEL-NEUROPHYSINS AND VLDV-NEUROPHYSINS FROM GOOSE NEUROHYPOPHYSIS 10.1016/0143-4179(89)90090-5

PARTICULAR PROCESSING OF PRO-OPIOMELANOCORTIN IN XENOPUS-LAEVIS INTERMEDIATE PITUITARY - SEQUENCING OF ALPHA-MELANOCYTE-STIMULATING, AND BETA-MELANOCYTE-STIMULATING HORMONES 10.1016/0014-5793(89)80224-8

DUAL DUPLICATION OF NEUROHYPOPHYSEAL HORMONES IN AN AUSTRALIAN MARSUPIAL - MESOTOCIN, OXYTOCIN, LYSINE VASOPRESSIN AND ARGININE VASOPRESSIN IN A SINGLE GLAND OF THE NORTHERN BANDICOOT (ISOODON-MACROURUS) 10.1016/0006-291x(88)90691-2

ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOPRESSIN AND MSEL-NEUROPHYSIN FROM GUINEA-PIG NEUROINTERMEDIATE PITUITARY 10.1016/0143-4179(88)90025-x

NEUROHYPOPHYSEAL HORMONES OF THE 1-MONTH-OLD BOVINE FETUS - ABSENCE OF VASOTOCIN DURING MAMMAL DEVELOPMENT 10.1016/0014-5793(88)80113-3

THE DISTRIBUTION OF LYSINE VASOPRESSIN (LYSIPRESSIN) IN PLACENTAL MAMMALS - A REINVESTIGATION OF THE HIPPOPOTAMIDAE (HIPPOPOTAMUS-AMPHIBIUS) AND TAYASSUIDAE (TAYASSU-ANGULATUS) FAMILIES 10.1016/0016-6480(88)90277-8

EVOLUTION OF MARSUPIALS TRACED BY THEIR NEUROHYPOPHYSEAL HORMONES - MICROIDENTIFICATION OF MESOTOCIN AND ARGININE VASOPRESSIN IN 2 AUSTRALIAN FAMILIES, DASYURIDAE AND PHASCOLARCTIDAE 10.1016/0016-6480(87)90195-x

GUINEA-PIG NEUROHYPOPHYSEAL HORMONES - PECULIAR PROCESSING OF THE 3-DOMAIN VASOPRESSIN PRECURSOR 10.1016/0014-5793(87)81294-2

Hexim1, a Novel Regulator of Leptin Function, Modulates Obesity and Glucose Disposal 10.1210/me.2015-1211

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus 10.1128/jvi.00404-16

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5

Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope 10.1371/journal.ppat.1005476

Recent advances in human viruses imaging studies 10.1002/jobm.201500575

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A 10.1128/jvi.00192-15

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Regulation of core expression during the hepatitis C virus life cycle 10.1099/vir.0.070433-0

FTO contributes to hepatic metabolism regulation through regulation of leptin action and STAT3 signalling in liver 10.1186/1478-811x-12-4

Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis 10.5812/hepatmon.17812

Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022

Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors 10.1016/j.bmcl.2014.07.051

Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells 10.1371/journal.pone.0074491

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry 10.1002/hep.24803

Hepatitis C Virus and Natural Compounds: A New Antiviral Approach? 10.3390/v4102197

Role of low-density lipoprotein receptor in the hepatitis C virus life cycle 10.1002/hep.25501

Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway 10.1074/jbc.M111.224857

HCV replication and assembly: a play in one act 10.2217/fvl.11.69

Hepatitis C Virus Assembly Imaging 10.3390/v3112238

Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies 10.1016/j.yexcr.2011.08.018

NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly 10.1371/journal.ppat.1001278

Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein 10.1099/vir.0.015339-0

Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity 10.1128/jvi.01393-10

Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication 10.1128/jvi.01190-09

LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice 10.1172/jci34997

Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins 10.1099/vir.0.82872-0

Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity 10.1073/pnas.0706671104

Hepatitis C virus entry depends on clathrin-mediated endocytosis 10.1128/jvi.00024-06

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus 10.1128/jvi.80.6.2832-2841.2006

Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis 10.1038/sj.emboj.7600989

Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis 10.1128/jvi.79.16.10826-10829.2005

Interactions between virus proteins and host cell membranes during the viral life cycle 10.1016/s0074-7696(05)45006-8

Significance of prohormone convertase 2, PC2, mediated initial cleavage at the proglucagon interdomain site, Lys70-Arg71, to generate glucagon 10.1210/en.2004-1118

Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway 10.1074/jbc.M400508200

The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals 10.1128/jvi.78.22.12591-12602.2004

Visualization of TGN to endosome trafficking through fluorescently labeled MPR and AP-1 in living cells 10.1091/mbc.E02-06-0338

Dynamic processing of neuropeptides - Sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport 10.1385/jmn:18:3:223

Yeast Vps55p, a functional homolog of human obesity receptor gene-related protein, is involved in late endosome to vacuole trafficking 10.1091/mbc.01-12-0597

Targeting of lysosomal proteins 10.1006/scdb.2000.0168

Unique evolution of neurohypophysial hormones in cartilaginous fishes: Possible implications for urea-based osmoregulation 10.1002/(sici)1097-010x(19991001)284:5<475::aid-jez2>3.0.co;2-9

Adaptive evolution of water homeostasis regulation in amphibians: Vasotocin and hydrins 10.1016/s0248-4900(97)83380-1

Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2 10.1073/pnas.94.13.6646

Molecular evolution of neurohypophysial hormones in relation to osmoregulation: the two fish options 10.1023/a:1007720909113

Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication 10.1111/cmi.12804

Entry and release of hepatitis C virus in polarized human hepatocytes. 10.1128/jvi.00478-17

An ecological approach to discover new bioactive extracts and products: the case of extremophile plants. 10.1111/jphp.12728

Endospanin1 affects oppositely body weight regulation and glucose homeostasis by differentially regulating central leptin signaling. 10.1016/j.molmet.2016.10.009

Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. 10.1128/jvi.00048-17

Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics. 10.1016/j.jviromet.2017.04.009

Hepatitis C virus life cycle and lipid metabolism. 10.3390/biology3040892

Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity 10.1172/jci.insight.98081

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17

Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses 10.1099/jgv.0.001099

Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein 10.1128/JVI.01459-18

QuantIF: An ImageJ Macro to Automatically Determine the Percentage of Infected Cells after Immunofluorescence 10.3390/v11020165

Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants 10.3390/pathogens10020172

Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses 10.1101/2021.05.19.444823

The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal. 10.1074/jbc.ra119.008964

Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release. 10.1007/s00018-020-03745-y

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. 10.1128/jvi.02009-18

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress 10.3390/cells10082047

Karin Seron

Seron Karin

ORCID: 0000-0002-9667-133X

Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication 10.1111/cmi.12572

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5

Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans 10.1128/jvi.03647-14

Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro 10.1371/journal.pone.0142539

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors 10.1128/jvi.01402-14

Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022

Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors 10.1016/j.bmcl.2014.07.051

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry 10.1002/hep.24803

Hepatitis C Virus and Natural Compounds: A New Antiviral Approach? 10.3390/v4102197

Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway 10.1074/jbc.M111.224857

Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein 10.1099/vir.0.015339-0

Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity 10.1073/pnas.0706671104

ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity 10.2337/diabetes.55.02.06.db05-0971

Distinct impaired regulation of SOCS3 and long and short isoforms of the leptin receptor in visceral and subcutaneous fat of lean and obese women 10.1016/j.bbrc.2006.07.068

Genetic study of the CD36 gene In a French diabetic population 10.1016/s1262-3636(07)70143-x

GAD2 on chromosome 10p12 is a candidate gene for human obesity 10.1371/journal.pbio.0000068

Molecular cloning, functional complementation in Saccharomyces cerevisiae and enzymatic properties of phosphatidylinositol synthase from the protozoan parasite Toxoplasma gondii 10.1046/j.1432-1327.2000.01749.x

Disruption of six novel genes from the left arm of chromosome XV of Saccharomyces cerevisiae and basic phenotypic analysis of the generated mutants 10.1002/(sici)1097-0061(19990115)15:1<73::aid-yea341>3.0.co;2-q

Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase 10.1016/s0166-0934(96)02166-0

Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase (vol 64, pg 181, 1997) 10.1016/s0166-0934(96)02249-5

Expression of the 69K movement protein of turnip yellow mosaic virus in insect cells 10.1006/viro.1996.0246

Gene expression from viral RNA genomes 10.1007/bf00039391

Vascular movement of plant viruses 10.1094/mpmi-9-0435

IN-VITRO TRANSCRIPTS OF TURNIP YELLOW MOSAIC-VIRUS ENCOMPASSING A LONG 3' EXTENSION OR PRODUCED FROM A FULL-LENGTH CDNA CLONE HARBORING A 2 KB-LONG PCR-AMPLIFIED SEGMENT ARE INFECTIOUS 10.1016/s0923-2516(06)80049-x

Entry and release of hepatitis C virus in polarized human hepatocytes. 10.1128/jvi.00478-17

An ecological approach to discover new bioactive extracts and products: the case of extremophile plants. 10.1111/jphp.12728

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. 10.1128/jvi.00404-16

Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin. 10.1016/j.antiviral.2016.07.011

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus 10.1101/325126

Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource. 10.1016/j.jep.2020.112735

Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus. 10.1021/acsami.9b15032

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. 10.1128/jvi.02009-18

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226

Correction for Belouzard et al., "Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes". 10.1128/jvi.00309-18

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

A yeast t-SNARE involved in endocytosis. 10.1091/mbc.9.10.2873

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Philip Meuleman

Meuleman Philip

ORCID: 0000-0001-6821-234X

Blocking HCV entry as potential antiviral therapy 10.2217/fvl.12.47

HCV animal models and liver disease 10.1016/j.jhep.2014.07.013

Human but Not Mouse Hepatocytes Respond to Interferon-Lambda In Vivo 10.1371/journal.pone.0087906

Hepatitis C virus infection and related liver disease: the quest for the best animal model 10.3389/fmicb.2013.00212

The emergence of hepatitis E virus in Europe 10.2217/fvl.15.29

Murine IL-2 receptor beta chain blockade improves human leukocyte engraftment in SCID mice 10.1002/(sici)1521-4141(199810)28:10<3221::aid-immu3221>3.0.co;2-s

Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection 10.1172/jci70349

Molecular detection and quantification of Plasmodium falciparum-infected human hepatocytes in chimeric immune-deficient mice 10.1186/1475-2875-12-430

Human Skin-Derived Precursor Cells Are Poorly Immunogenic and Modulate the Allogeneic Immune Response 10.1002/stem.1692

Metabolism of methylstenbolone studied with human liver microsomes and the uPA +/+ -SCID chimeric mouse model 10.1002/bmc.3105

Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1 10.1074/jbc.m114.617787

Is hepatitis E virus an emerging problem in industrialized countries? 10.1002/hep.27990

Animal models for the study of HCV 10.1016/j.coviro.2015.04.009

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody 10.1038/nbt.3179

Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1 10.1002/hep.28111

Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model 10.1093/jac/dkv019

G09 : Targeting a host-cell entry factor barricades antiviral resistant HCV variants from on-therapy breakthrough in human-liver mice 10.1016/s0168-8278(15)30058-1

P0674 : Clinically approved T-type calcium channel inhibitors prevent hepatitis C virus (HCV) membrane fusion in a genotype-dependent manner 10.1016/s0168-8278(15)30878-3

P0676 : Clearance of persistent hepatitis c virus infection using a monoclonal antibody specific for tight junction protein claudin-1 10.1016/s0168-8278(15)30880-1

In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200 10.1002/rcm.6673

In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) 10.1007/s11419-013-0179-4

Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum 10.1186/1475-2875-13-136

Artemisinin Analogues as Potent Inhibitors of In Vitro Hepatitis C Virus Replication 10.1371/journal.pone.0081783

A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites 10.7554/elife.03582

Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents 10.1002/hep.27196

Cell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted Variant 10.1128/jvi.01362-07

Immune Suppression Uncovers Endogenous Cytopathic Effects of the Hepatitis B Virus 10.1128/jvi.80.6.2797-2807.2006

O.055 The human liver-uPA-SCID mouse: a chimeric rodent model for the study of viral hepatitis 10.1016/s1386-6532(06)80061-2

A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice 10.1016/s0006-291x(03)01388-3

Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity 10.1128/jvi.02356-06

PREVENTION OF HEPATITIS B INFECTIONS : VACCINATION AND ITS LIMITATIONS 10.1179/acb.2001.032

101 HUMAN MONOCLONAL ANTIBODIES TARGETING SR-BI PREVENT HCV ENTRY AND VIRAL SPREAD IN VIVO 10.1016/s0168-8278(11)60103-7

827 EXPERIMENTAL HCV VACCINE COMBINING ADENOVIRUS AND PROTEIN ELICITS POTENT T-CELL RESPONSES AND NEUTRALIZING ANTIBODIES IN RODENTS 10.1016/s0168-8278(12)60839-3

861 THE LECTIN GRIFFITHSIN HAS ANTIVIRAL ACTIVITY AGAINST HEPATITIS C VIRUS IN VITRO AND IN VIVO 10.1016/s0168-8278(12)60873-3

Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization 10.1128/jvi.01594-10

Griffithsin Has Antiviral Activity against Hepatitis C Virus 10.1128/aac.00633-11

In Vivo Inhibition of Anti-Hepatitis B Virus Core Antigen (HBcAg) Immunoglobulin G Production by HBcAg-Specific CD4+ Th1-Type T-Cell Clones in a hu-PBL-NOD/SCID Mouse Model 10.1128/jvi.75.23.11449-11456.2001

O.053 The human liver uPA-SCID mouse, a preclinical model to test anti-hepatitis C compounds 10.1016/s1386-6532(06)80060-0

Role of the Hepatitis C Virus Core+1 Open Reading Frame and Core cis-Acting RNA Elements in Viral RNA Translation and Replication 10.1128/jvi.01640-08

Development and Application of Hepatitis C Reporter Viruses with Genotype 1 to 7 Core-Nonstructural Protein 2 (NS2) Expressing Fluorescent Proteins or Luciferase in Modified JFH1 NS5A 10.1128/jvi.00049-11

Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses 10.1128/jvi.03574-13

Animal Models to Study Hepatitis C Virus Infection. 10.3389/fimmu.2018.01032

Absence of zoonotic hepatitis E virus infection in Flemish dairy cows. 10.1016/j.ijfoodmicro.2018.05.009

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. 10.1038/s41598-018-24762-9

Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues. 10.1002/hep4.1152

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1. 10.1016/j.virol.2017.10.019

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. 10.1016/j.antiviral.2017.10.015

Murine Tissues of Human Liver Chimeric Mice Are Not Susceptible to Hepatitis E Virus Genotypes 1 and 3. 10.1093/infdis/jix422

Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. 10.1053/j.gastro.2017.09.020

Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma. 10.1016/j.antiviral.2017.02.011

Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. 10.1016/j.antiviral.2017.01.001

Successful Engraftment of Human Hepatocytes in uPA-SCID and FRG® KO Mice. 10.1007/978-1-4939-6506-9_8

Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. 10.1038/nmicrobiol.2016.247

Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. 10.1128/mbio.01915-16

Hepatitis E virus in acute liver failure: An unusual suspect? 10.1002/hep.28759

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. 10.1128/jvi.00404-16

Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. 10.3390/v8060176

Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line. 10.1099/jgv.0.000493

Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. 10.1136/gutjnl-2015-311109

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. 10.1002/hep.28428

In vitro and in vivo metabolism studies of dimethazine. 10.1002/bmc.3668

Metabolic studies of prostanozol with the uPA-SCID chimeric mouse model and human liver microsomes. 10.1016/j.steroids.2016.01.005

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice. 10.1136/gutjnl-2015-310300

Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies. 10.1053/j.gastro.2015.09.014

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. 10.1136/gutjnl-2014-309045

Host cell mTORC1 is required for HCV RNA replication. 10.1136/gutjnl-2014-308971

Assessment of Parasite Liver-Stage Burden in Human-Liver Chimeric Mice. 10.1007/978-1-4939-2815-6_5

Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. 10.3748/wjg.v20.i43.15975

Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. 10.1136/gutjnl-2012-304299

Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice 10.1016/j.jhep.2012.02.018

The Green Tea Polyphenol, Epigallocatechin-3-Gallate, Inhibits Hepatitis C Virus Entry 10.1002/hep.24610

In Vivo Evaluation of the Cross-Genotype Neutralizing Activity of Polyclonal Antibodies Against Hepatitis C Virus 10.1002/hep.24171

Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice 10.1016/j.jhep.2010.03.024

Steroid metabolism in chimeric mice with humanized liver 10.1002/dta.67

The uPA(+/+)-SCID Mouse with Humanized Liver as a Model for in Vivo Metabolism of 4-Androstene-3,17-dione 10.1124/dmd.109.028183

Anti-CD81 Antibodies Can Prevent a Hepatitis C Virus Infection In Vivo 10.1002/hep.22547

Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain 10.1002/hep.22244

Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro 10.1073/pnas.0511218103

Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera 10.1002/hep.20657

Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. 10.1016/j.antiviral.2017.09.006

The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo. 10.1016/j.antiviral.2018.07.010

Methylene Blue Treatment of Grafts During Cold Ischemia Time Reduces the Risk of Hepatitis C Virus Transmission. 10.1093/infdis/jiy386

Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain. 10.1128/jvi.00939-18

Erratum: Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. 10.1038/nmicrobiol.2017.12

A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. 10.1016/j.jhep.2019.01.033

Animal Models for Hepatitis E virus. 10.3390/v11060564

Hepatitis E virus prevalence in Flemish blood donors. 10.1111/jvh.13161

Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis. 10.1093/infdis/jiz171

New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle. 10.1038/s41598-019-42737-2

Infectivity and stability of hepatitis C virus in different perfusion solutions. 10.1111/tid.13135

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections. 10.1093/infdis/jiaa036

Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes. 10.1073/pnas.1919035117

Robust hepatitis E virus infection and transcriptional response in human hepatocytes. 10.1073/pnas.1912307117

Updates in Hepatitis E virus (HEV) field; lessons learned from human liver chimeric mice. 10.1002/rmv.2086

Thermostability of seven hepatitis C virus genotypes in vitro and in vivo 10.1111/jvh.12055

A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo 10.1002/hep.24692

STAT transcriptional activity is controlled by regulated deacetylation 10.1016/j.cyto.2012.06.223

The Sin3a repressor complex is a master regulator of STAT transcriptional activity 10.1073/pnas.1206458109

Discovery of (7R)-14-Cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic Acid (MK-3281), a Potent and Orally Bioavailable Finger-Loop Inhibitor of the Hepatitis C Virus NS5B Polymerase 10.1021/jm1013105

Lipoprotein Lipase Inhibits Hepatitis C Virus (HCV) Infection by Blocking Virus Cell Entry 10.1371/journal.pone.0026637

Metabolic studies with promagnon, methylclostebol and methasterone in the uPA(+/+)-SCID chimeric mice 10.1016/j.jsbmb.2011.06.010

Challenge Pools of Hepatitis C Virus Genotypes 1-6 Prototype Strains: Replication Fitness and Pathogenicity in Chimpanzees and Human Liver-Chimeric Mouse Models 10.1086/651579

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation 10.1084/jem.20090766

Combination of liquid-chromatography tandem mass spectrometry in different scan modes with human and chimeric mouse urine for the study of steroid metabolism 10.1002/dta.56

Detection and Characterization of a New Metabolite of 17 alpha-Methyltestosterone 10.1124/dmd.109.028373

Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry 10.1016/j.steroids.2009.05.004

HCV Animal Models: A Journey of More than 30 Years 10.3390/v1020222

Production of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing Mutations 10.1371/journal.ppat.1000475

uPA(+/+)-SCID Mouse with Humanized Liver as a Model for In Vivo Metabolism of Exogenous Steroids: Methandienone as a Case Study 10.1373/clinchem.2008.119396

Development and validation of a quantitative gas chromatography-mass spectrometry method for the detection of endogenous androgens in mouse urine 10.1016/j.chroma.2007.11.077

The human liver-uPA-SCID mouse: A model for the evaluation of antiviral compounds against HBV and HCV 10.1016/j.antiviral.2008.07.006

Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse 10.1053/j.gastro.2007.07.007

Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection 10.1016/j.cca.2005.09.022

The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level 10.1016/j.jim.2004.01.001

Jean Dubuisson

Dubuisson Jean

ORCID: 0000-0003-1626-7693

Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses 10.1016/j.jhep.2015.12.021

Hepatitis C Virus Resistance to Carbohydrate-Binding Agents 10.1371/journal.pone.0149064

Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus 10.1128/JVI.00404-16

Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication 10.1111/cmi.12572

Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin 10.1016/j.antiviral.2016.07.011

Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope 10.1371/journal.ppat.1005476

Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver 10.1136/gutjnl-2015-311109

Alphacoronaviruses Detected in French Bats Are Phylogeographically Linked to Coronaviruses of European Bats 10.3390/v7122937

Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry 10.1039/c4nr03875d

Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans 10.1128/JVI.03647-14

Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro 10.1371/journal.pone.0142539

HCV envelope glycoproteins in virion assembly and entry 10.2217/FVL.14.114

Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion 10.1128/JVI.00991-15

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A 10.1128/JVI.00192-15

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/JVI.01473-15

Regulation of core expression during the hepatitis C virus life cycle 10.1099/vir.0.070433-0

A chimeric protein encompassing hepatitis C virus epitopes is able to elicit both humoral and cell-mediated immune responses in mice 10.1002/bab.1223

Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution 10.1128/JVI.01745-13

HCV-specific immune responses induced by CIGB-230 in combination with IFN-alpha plus ribavirin 10.3748/wjg.v20.i1.148

Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis 10.5812/hepatmon.17812

Hepatitis C virus life cycle and lipid metabolism 10.3390/biology3040892

Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein 10.1371/journal.pone.0111333

Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors 10.1128/JVI.01402-14

Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion 10.3390/v6031149

Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation 10.1016/j.vaccine.2014.01.046

Virology and cell biology of the hepatitis C virus life cycle - An update 10.1016/j.jhep.2014.06.031

Additional Glycosylation Within a Specific Hypervariable Region of Subtype 3a of Hepatitis C Virus Protects Against Virus Neutralization 10.1093/infdis/jit376

Disulfide Bonds in Hepatitis C Virus Glycoprotein E1 Control the Assembly and Entry Functions of E2 Glycoprotein 10.1128/JVI.02659-12

EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry 10.1111/cmi.12112

Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells 10.1371/journal.pone.0074491

Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus 10.1371/journal.pone.0070809

Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral Therapeutics 10.1021/am403770q

Structural knowledge of HCV envelope protein region recognized by broadly neutralizing antibodies 10.2217/fvl.13.75

The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus 10.1002/hep.26273

Virus-neutralizing antibodies to hepatitis C virus 10.1111/jvh.12094

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry 10.1002/hep.24803

Hepatitis C Virus and Natural Compounds: A New Antiviral Approach? 10.3390/v4102197

New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets 10.1136/gutjnl-2012-302048

Role of low-density lipoprotein receptor in the hepatitis C virus life cycle 10.1002/hep.25501

Three Different Functional Microdomains in the Hepatitis C Virus Hypervariable Region 1 (HVR1) Mediate Entry and Immune Evasion 10.1074/jbc.M112.382341

Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein 10.1099/vir.0.028092-0

Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships 10.1099/vir.0.034314-0

Griffithsin Has Antiviral Activity against Hepatitis C Virus 10.1128/AAC.00633-11

HCV replication and assembly: a play in one act 10.2217/FVL.11.69

Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype 10.1128/JVI.01332-10

Hepatitis C Virus Assembly Imaging 10.3390/v3112238

Hepatitis C virus entry into the hepatocyte 10.2478/s11535-011-0076-y

Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies 10.1016/j.yexcr.2011.08.018

Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2 10.1128/JVI.02170-10

Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, and Their Effect on Hepatitis C Virus Infection 10.1074/jbc.M111.220103

NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly 10.1371/journal.ppat.1001278

The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response 10.3390/v3101909

Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus 10.1128/JVI.01180-10

Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein 10.1099/vir.0.015339-0

Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity 10.1128/JVI.01393-10

Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication 10.1128/JVI.01190-09

Last Stop Before Exit - Hepatitis C Assembly and Release as Antiviral Drug Targets 10.3390/v2081782

NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus 10.1074/jbc.M110.122895

Recent Advances in Hepatitis C Virus Cell Entry 10.3390/v2030692

Role of lipid metabolism in hepatitis C virus assembly and entry 10.1042/BC20090125

Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions 10.1128/JVI.01548-10

Enhanced anti-HCV activity of interferon alpha 17 subtype 10.1186/1743-422X-6-70

Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial 10.1111/j.1365-2893.2008.01058.x

N-glycans as contributors in the biological properties of the hepatitis C virus envelope proteins 10.1684/vir.2009.0270

Occludin, the final essential factor for HCV entry? 10.2217/FVL.09.13

Rapid synchronization of hepatitis C virus infection by magnetic adsorption 10.1016/j.jviromet.2008.11.015

The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry 10.1186/1471-2180-9-111

Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry 10.1111/j.1462-5822.2007.01070.x

Early steps of the hepatitis C virus life cycle 10.1111/j.1462-5822.2007.01107.x

Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein 10.1128/JVI.02582-07

Hepatitis C virus entry into host cells 10.1007/s00018-007-7291-8

Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus 10.1086/589777

Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent 10.1128/JVI.01443-07

The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry 10.1371/journal.pone.0001866

CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection 10.1128/JVI.01573-06

Hepatitis C virus proteins 10.3748/wjg.v13.i17.2406

Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus 10.1073/pnas.0705522104

New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu 10.1186/1742-4690-4-8

Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors 10.1099/vir.0.82465-0

Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins 10.1099/vir.0.82872-0

The Alphavirus 6K protein activates endogenous ionic conductances when expressed in Xenopus oocytes 10.1007/s00232-007-9003-6

The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein 10.1128/JVI.00127-07

Transmembrane domains of hepatitis C virus envelope glycoproteins: Residues involved in E1E2 heterodimerization and involvement of these domains in virus entry 10.1128/JVI.02198-06

Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles 10.1099/vir.0.81503-0

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans 10.1074/jbc.M602431200

Hepatitis C virus entry depends on clathrin-mediated endocytosis 10.1128/JVI.00024-06

Hepatitis C virus entry: potential receptors and their biological functions 10.1099/vir.0.81646-0

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI 10.1074/jbc.M602706200

High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry 10.1099/vir.0.81932-0

Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system 10.1002/hep.21406

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus 10.1128/JVI.80.6.2832-2841.2006

Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2 10.1128/JVI.79.21.13199-13208.2005

Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets 10.1099/vir.0.81169-0

Basic residues in hyervariable region 1 of hepatitis C virus envelope glycoprotein E2 contribute to virus entry 10.1128/JVI.79.24.15331-15341.2005

Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis 10.1128/JVI.79.16.10826-10829.2005

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus 10.1002/hep.20542

Contribution of the charged residues of hepatitis C virus glycoprotein E2 transmembrane domain to the functions of the E1E2 heterodimer 10.1099/vir.0.81140-0

High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I 10.1074/jbc.M411600200

Interactions between virus proteins and host cell membranes during the viral life cycle 10.1016/S0074-7696(05)45006-8

Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins 10.1128/JVI.79.13.8400-8409.2005

Characterization of functional hepatitis C virus envelope glycoproteins 10.1128/JVI.78.6.2994-3002.2004

Functional hepatitis C virus envelope glycoproteins 10.1016/j.biolcel.2004.03.008

Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions 10.1128/JVI.78.17.9224-9232.2004

Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein 10.4049/jimmunol.173.1.446

Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication 10.1007/s00705-003-0291-6

Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions 10.1074/jbc.M406315200

Structural biology of hepatitis C virus 10.1002/hep.20032

The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals 10.1128/JVI.78.22.12591-12602.2004

Another putative receptor for hepatitis C virus 10.1002/hep.510370327

CD81-dependent binding of hepatitis C virus E1E2 heterodimers 10.1128/JVI.77.19.10677-10683.2003

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor 10.1074/jbc.M305289200

Characterization of the expression of the hepatitis C virus F protein 10.1099/vir.0.19065-0

Glycosylation of hepatitis C virus envelope proteins 10.1016/S0300-9084(03)00004-X

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes 10.1084/jem.20021756

Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope 10.1128/JVI.77.2.813-820.2003

Topology of hepatitis C virus envelope glycoproteins 10.1002/rmv.391

Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines 10.1128/JVI.76.3.1181-1193.2002

Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line 10.1093/glycob/12.2.95

Interaction of hepatitis C virus proteins with host cell membranes and lipids 10.1016/S0962-8924(02)02383-8

Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines 10.1006/viro.2001.1212

Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment 10.1074/jbc.M111020200

Subcellular localization and topology of the p7 polypeptide of hepatitis C virus 10.1128/JVI.76.8.3720-3730.2002

Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins 10.1093/emboj/cdf295

Biogenesis of hepatitis C virus envelope glycoproteins 10.1099/0022-1317-82-11-2589

Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2 10.1099/0022-1317-82-7-1629

Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization 10.1053/jhep.2001.22175

Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients 10.1128/JVI.75.17.8240-8250.2001

Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding 10.1099/0022-1317-81-12-2873

Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein 10.1128/JVI.74.2.702-709.2000

Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein 10.1074/jbc.M004326200

Reciprocal relationship between alpha 1,2 mannosidase processing and reglucosylation in the rough endoplasmic reticulum of Man-P-Dol deficient cells 10.1046/j.1432-1327.2000.01111.x

The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization 10.1074/jbc.M003003200

Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex 10.1099/0022-1317-80-4-887

Characterization of aggregates of hepatitis C virus glycoproteins 10.1099/0022-1317-80-12-3099

Retention and degradation of N-glycoproteins in the rough endoplasmic reticulum 10.1023/A:1020228725997

Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties 10.1006/viro.1998.9202

Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval 10.1074/jbc.273.48.32088

Characterization of truncated forms of hepatitis C virus glycoproteins 10.1099/0022-1317-78-9-2299

SYNTHESIS AND PROCESSING OF BOVINE HERPESVIRUS-1 GLYCOPROTEIN-H 10.1016/S0042-6822(95)80083-2

ATTACHMENT OF THE GAMMAHERPESVIRUS BOVINE HERPESVIRUS-4 IS MEDIATED BY THE INTERACTION OF GP8 GLYCOPROTEIN WITH HEPARIN-LIKE MOIETIES ON THE CELL-SURFACE 10.1006/viro.1993.1471

IDENTIFICATION OF 108-K, 93-K, AND 42-K GLYCOPROTEINS OF BOVINE HERPESVIRUS-1 BY MONOCLONAL-ANTIBODIES 10.1007/BF01309747

EPIDEMIOLOGIC EVALUATION OF A MONOCLONAL ELISA DETECTING BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGENS IN FIELD BLOOD-SAMPLES OF PERSISTENTLY INFECTED CATTLE 10.1016/0166-0934(92)90010-B

IDENTIFICATION AND CHARACTERIZATION OF GLYCOPROTEIN-GP1 OF BOVINE HERPESVIRUS TYPE-4 10.1099/0022-1317-73-5-1293

MECHANISMS OF BOVINE HERPESVIRUS TYPE-1 NEUTRALIZATION BY MONOCLONAL-ANTIBODIES TO GLYCOPROTEIN-GI, GLYCOPROTEIN-GIII AND GLYCOPROTEIN-GIV 10.1099/0022-1317-73-8-2031

MOLECULAR-BIOLOGY OF BOVINE HERPESVIRUS TYPE-4 10.1016/0378-1135(92)90037-T

PROTEINS OF BOVINE HERPESVIRUS TYPE-4 RELEASED INTO THE CULTURE-MEDIUM OF PRODUCTIVELY INFECTED-CELLS - IDENTIFICATION OF A 135K GLYCOPROTEIN INVOLVED IN VIRAL ATTACHMENT 10.1099/0022-1317-73-1-189

A MONOCLONAL ELISA FOR BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGEN-DETECTION IN PERSISTENTLY INFECTED CATTLE 10.1016/0166-0934(91)90133-K

ANTIGENIC AND GENOMIC IDENTITY BETWEEN SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4 10.1099/0022-1317-72-3-715

BOVINE HERPESVIRUS-4 ISOLATES - A COMPARISON OF 3 MAJOR GLYCOPROTEINS 10.1016/0378-1135(91)90132-Y

CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVINE VIRAL DIARRHEA VIRUS - EVIDENCE OF A NEUTRALIZING ACTIVITY AGAINST GP48 IN THE PRESENCE OF GOAT ANTI-MOUSE IMMUNOGLOBULIN SERUM 10.1099/0022-1317-72-5-1195

COMPARISON OF PROTEINS OF SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4 10.1099/0022-1317-72-5-1145

FAILURE TO INFECT CATS WITH BOVINE HERPESVIRUS TYPE-4 STRAIN MOVAR 33/63 10.1136/vr.128.26.614

GENOMIC DIVERSITY AMONG BOVINE HERPESVIRUS-4 FIELD ISOLATES 10.1007/BF01319227

TEMPORAL CONTROL OF BOVINE HERPESVIRUS TYPE-4 GLYCOPROTEIN-SYNTHESIS 10.1099/0022-1317-72-6-1429

Bovine herpesvirus 4 genome: cloning, mapping and strain variation analysis 10.1099/0022-1317-71-1-133

Neutralization of bovine herpesvirus type 4 by pairs of monoclonal antibodies raised against two glycoproteins and identification of antigenic determinants involved in neutralization 10.1099/0022-1317-71-3-647

EXPERIMENTAL-INFECTION OF BULLS WITH A GENITAL ISOLATE OF BOVINE HERPESVIRUS-4 AND REACTIVATION OF LATENT VIRUS WITH DEXAMETHASONE 10.1016/0378-1135(89)90022-9

PRODUCTION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVID HERPESVIRUS-4 10.1016/0378-1135(89)90096-5

PROTEINS SPECIFIED BY BOVINE HERPESVIRUS TYPE-4 - STRUCTURAL PROTEINS OF THE VIRION AND IDENTIFICATION OF 2 MAJOR GLYCOPROTEINS BY USING MONOCLONAL-ANTIBODIES 10.1099/0022-1317-70-7-1743

BIOLOGICAL AND BIOCHEMICAL-COMPARISON OF BOVID HERPESVIRUS-4 STRAINS 10.1016/0378-1135(88)90015-6

Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly 10.1128/JVI.00048-17

Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination 10.1111/pbi.12743

Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly 10.1016/j.biochi.2017.06.009

Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics 10.1016/j.jviromet.2017.04.009

Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes 10.1128/JVI.00478-17

Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus 10.1111/jvh.12767

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1 10.1016/j.virol.2017.10.019

Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein 10.1053/j.gastro.2017.09.020

Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication 10.1111/cmi.12804

Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes 10.1053/j.gastro.2018.03.020

Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial) 10.1007/s40271-017-0232-1

Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study 10.1371/journal.pone.0145105

The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients 10.1111/jvh.12433

Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain 10.1128/JVI.00939-18

HCoV-229E spike protein fusion activation by trypsin-like serine proteases is mediated by proteolytic processing in the S2 ' region 10.1099/jgv.0.001074

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17

Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses 10.1099/jgv.0.001099

Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies 10.3389/fimmu.2018.00910

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus Replication 10.1101/469361

Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein 10.1128/JVI.01459-18

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus , Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/JVI.02009-18

Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir 10.1016/j.antiviral.2019.05.002

New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle 10.1038/s41598-019-42737-2

Le virus de l’hépatite E 10.1051/medsci/2018299

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture 10.1371/journal.pone.0198226

Function of the HCV E1 envelope glycoprotein in viral entry and assembly 10.2217/fvl-2018-0180

Similarities and Differences Between HCV Pseudoparticle (HCVpp) and Cell Culture HCV (HCVcc) in the Study of HCV 10.1007/978-1-4939-8976-8_2

Use of whole-genome sequencing in the molecular investigation of care-associated HCoV-OC43 infections in a hematopoietic stem cell transplant unit 10.1016/j.jcv.2019.104206

A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice 10.1186/s12879-019-4571-5

Hepatitis C Virus Improves Human Tregs Suppressive Function and Promotes Their Recruitment to the Liver 10.3390/cells8101296

Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus 10.1021/acsami.9b15032

The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal 10.1074/jbc.ra119.008964

Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection 10.1111/tra.12680

Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model 10.1101/2020.04.22.056754

Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers 10.1101/2020.05.12.20098236

Les coronavirus, ennemis incertains 10.1051/medsci/2020113

Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource 10.1016/j.jep.2020.112735

Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants 10.3390/pathogens10020172

Fluoxetine Can Inhibit SARS-CoV-2 In Vitro 10.3390/microorganisms9020339

Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds 10.3390/pathogens10070861

Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress 10.3390/cells10082047

Lander Foquet

Foquet Lander

ORCID: 0000-0001-9235-0814

http://about.me/lander.foquet

Molecular detection and quantification of Plasmodium falciparum-infected human hepatocytes in chimeric immune-deficient mice 10.1186/1475-2875-12-430

Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. 10.1172/JCI70349

Contribution of the Ly49E natural killer receptor in the immune response to Plasmodium berghei infection and control of hepatic parasite development. 10.1371/journal.pone.0087463

Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. 10.1186/1475-2875-13-136

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. 10.1128/jvi.00404-16

Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. 10.1136/gutjnl-2015-311109

Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model. 10.1093/jac/dkv019

Assessment of Parasite Liver-Stage Burden in Human-Liver Chimeric Mice. 10.1007/978-1-4939-2815-6_5

A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. 10.7554/elife.03582

Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma 10.1016/j.antiviral.2017.02.011

Assessing drug efficacy against Plasmodium falciparum liver stages in vivo 10.1172/jci.insight.92587

Presence of CXCR4-Using HIV-1 in patients with recently diagnosed infection: Correlates and evidence for transmission 10.1093/infdis/jir714

Consumptive coagulopathy of severe yellow fever occurs independently of hepatocellular tropism and massive hepatic injury 10.1073/pnas.2014096117

Ahmed Atef Mesalam

Mesalam Ahmed Atef / Ahmed Atef Mesalam

ORCID: 0000-0003-4605-2976

Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization 10.3748/wjg.v20.i43.15975

Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate 10.1007/s00705-009-0500-z

Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus 10.1128/JVI.00404-16

Animal models to study hepatitis C virus infection 10.3389/fimmu.2018.01032

Polyphenols inhibit hepatitis C virus entry by a new mechanism of action 10.1128/JVI.01473-15

Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line 10.1099/jgv.0.000493

Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate 10.1002/jmv.24977

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice 10.1136/gutjnl-2014-309045

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1 10.1016/j.virol.2017.10.019

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo 10.1016/j.antiviral.2017.10.015

Mouse systems to model hepatitis C virus treatment and associated resistance 10.3390/v8060176

Functional study of the C-Terminal part of the hepatitis C Virus E1 ectodomain 10.1128/JVI.00939-18

Induction of Oxidative Stress and Mitochondrial Dysfunction by Juglone Affects the Development of Bovine Oocytes 10.3390/ijms22010168

Hepatitis C Virus Vaccine Development: A Step Forward 10.1093/infdis/jiaa644

Nicotinamide Supplementation during the In Vitro Maturation of Oocytes Improves the Developmental Competence of Preimplantation Embryos: Potential Link to SIRT1/AKT Signaling 10.3390/cells9061550

Melatonin Abrogates the Anti-Developmental Effect of the AKT Inhibitor SH6 in Bovine Oocytes and Embryos 10.3390/ijms20122956

Melatonin Alleviates the Toxicity of High Nicotinamide Concentrations in Oocytes: Potential Interaction with Nicotinamide Methylation Signaling 10.1155/2021/5573357